Riding the Waves, Rising to the Challenge | Cell Valley Group Convenes Mid-Year Management Review and All-Staff Assembly

Riding the Waves, Rising to the Challenge | Cell Valley Group Convenes Mid-Year Management Review and All-Staff Assembly

Recently, Shenzhen Cell Valley successfully held its 2025 Mid-Year Management Review and All-Staff Assembly, marking a pivotal moment to reflect on achievements and chart the course for the future.

2025 Mid-Year Management Review

During the management review, department heads delivered comprehensive reports covering market expansion, R&D advancements, process optimization, quality assurance, and team building. They systematically analyzed performance metrics and key outcomes from the first half of the year.

Chairman Professor Shi Yuanyuan presided over the sessions, listening attentively to each report. He provided specific directives to address critical bottlenecks identified by various departments and outlined a strategic roadmap for the second half of the year.

2025 All-Staff Assembly

The all-staff assembly brought together employees from the Group’s headquarters in Shenzhen and its branches—including Deep Harbour Cell Valley , Guangdong Junhou Biotechnology, Jing-Shen Cell Valley, Hong Kong Cell Valley, and the Henan Branch—via a hybrid format of online and offline participation.

Moderated by Wei Zheng, Director of Administration, the meeting featured a keynote address by Chairman and General Manager Professor Shi Yuanyuan, who summarized the first half of the year’s progress and highlighted four key strategic pillars:

1. The Official Launch of Deep Harbour Cell Valley

In May 2025, Deep Harbour Cell Valley  was officially inaugurated as the Group’s hub for international business and medical services. Strategically located in Qianhai, Shenzhen, and integrated with Hong Kong, this new entity leverages synergies in research, industry, and policy to build a one-stop platform covering the entire Cell and Gene Therapy (CGT) value chain. Its scope includes medical services, innovative drug R&D, manufacturing, general wellness, and aesthetic anti-aging solutions. By capitalizing on Qianhai Free Trade Zone policies, Shen-Hong aims to accelerate the clinical translation and industrialization of cutting-edge technologies.

2. Strategic Expansion and Regulatory Milestones

The Group has established a robust multi-node network linking Shenzhen, Hong Kong, Zhongshan, and Beijing, with a workforce exceeding 100 employees. Significant regulatory breakthroughs include:

· ISO 9001:2015 Certification: Shenzhen Cell Valley recently secured this prestigious quality management certification.

· INCI Registration: The Group’s proprietary “Umbilical Cord Mesenchymal Stem Cell Vesicles” successfully achieved international INCI registration.

· FDA DMF Filing: Research outcomes on exosomes from Shenzhen Cell Valley have received relevant DMF (Drug Master File) filings with the US FDA, marking a major step in international standardization.

3. Operational Achievements

The first half of the year saw critical progress across multiple fronts, including CRO projects, proprietary pipelines, patent applications, major research grants, market expansion, and hospital ethics approvals.

4. Market Outlook and H2 Objectives

With China’s CGT market surpassing 10 billion RMB and the opening of four major Free Trade Zones, the industry faces unprecedented opportunities. In the second half of the year, the Company will focus on:

· Securing national, provincial, and municipal key projects.

· Obtying honors and qualifications.

· Expanding into international markets.

· Filing independent invention patents.

· Advancing IIT (Investigator-Initiated Trials) and clinical collaborations.

· Driving financing efforts.

· All resource allocation will be strictly market-oriented to ensure high-efficiency, sustainable growth.

Moving Forward Together

· These back-to-back meetings not only celebrated past achievements but also solidified a shared vision. Upholding the core values of “Innovation, Collaboration, and Win-Win,” the entire team is poised to ride the momentum, navigate challenges, and propel Shenzhen Cell Valley to new heights in the global cell therapy landscape.